Table. Baseline Participant Characteristics.
| Characteristic | No. (%) | P value | ||
|---|---|---|---|---|
| Gabapentin, 3600 mg | Gabapentin, 2700 mg | Gabapentin, 900 mg | ||
| Total participants, No. | 32 | 31 | 29 | NA |
| Age, median (IQR), y | 63.0 (56.8-68.8) | 62.0 (55.2-65.1) | 61.9 (54.3-64.6) | .43 |
| Sex | ||||
| Male | 28 (87.5) | 27 (87.1) | 27 (93.1) | .77 |
| Female | 4 (12.5) | 4 (12.9) | 2 (6.9) | |
| Race | ||||
| Racial minority groupa | 1 (3.1) | 1 (3.2) | 0 | >.99 |
| White | 31 (96.9) | 30 (96.8) | 29 (100) | |
| ECOG performance status | ||||
| 0 | 23 (71.9) | 23 (74.2) | 23 (79.3) | .76 |
| 1 | 8 (25.0) | 7 (22.6) | 6 (20.7) | |
| 2 | 1 (3.1) | 1 (3.2) | 0 | |
| BMI, median (IQR) | 29.3 (26.2-32.4) | 28.6 (24.3-31.3) | 29.9 (27.6-32.2) | .45 |
| Primary disease site | ||||
| Oropharynx | 27 (84.4) | 22 (71.0) | 21 (72.4) | .38 |
| Other | 5 (15.6) | 9 (29.0) | 8 (27.6) | |
| AJCC-7 cancer stage | ||||
| II | 0 | 2 (6.5) | 0 | .25 |
| III | 5 (15.6) | 9 (29.0) | 7 (24.1) | |
| IV | 27 (84.4) | 20 (64.5) | 22 (75.9) | |
| Feeding tube before radiotherapy | ||||
| No | 31 (96.9) | 29 (93.5) | 29 (100) | .65 |
| Yes | 1 (3.1) | 2 (6.5) | 0 | |
| Neck radiotherapy | ||||
| Unilateral | 10 (31.3) | 4 (12.9) | 5 (17.2) | .19 |
| Bilateral | 22 (68.8) | 27 (87.1) | 24 (82.8) | |
Abbreviations: AJCC-7, AJCC Cancer Staging Manual (7th edition); BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); ECOG, Eastern Cooperative Oncology Group; NA, not applicable.
a
Racial minority groups included Asian or Pacific Islander, Black or African American, and unreported (participants declined to report race).